A severe refractory COVID-19 patient responding to convalescent plasma; A case series

INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Hadi Mohammed, Hama-Ali, Hersh H., Ahmed, Sabah Nasraddin, Ali, Kosar Muhammad, Karadakhy, Kamaran Amin, Mahmood, Safeen Othman, Mahmood, Zana Hameed, Hamad Amin, Karmand Qadir, Atta, Peshnyar Muhammad, Nuradeen, Bryar Ezadeen, Mohammed, Shvan H., Salih, Rawezh Q., Baba, Hiwa O., Kakamad, Fahmi H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327024/
https://www.ncbi.nlm.nih.gov/pubmed/32637086
http://dx.doi.org/10.1016/j.amsu.2020.06.018
Descripción
Sumario:INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests. CONCLUSION: CP might be an effective therapy for severe COVID-19 patients.

Ejemplares similares